Insider Trading Arrangements |
3 Months Ended | 6 Months Ended |
|---|---|---|
|
Jul. 31, 2024
shares
|
Jul. 31, 2024
shares
|
|
| Trading Arrangements, by Individual | ||
| Non-Rule 10b5-1 Arrangement Adopted | false | |
| Non-Rule 10b5-1 Arrangement Terminated | false | |
| Michael Weintraub [Member] | ||
| Trading Arrangements, by Individual | ||
| Material Terms of Trading Arrangement | On June 6, 2024, Michael Weintraub, the chairperson of the Company’s Board of Directors, adopted a trading arrangement for the sale of securities of the Company’s common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Weintraub’s Rule 10b5-1 Trading Plan provides for the potential exercise of vested stock options and the associated sale of up to 55,152 shares of the Company’s common stock. The plan expires on September 30, 2025, or upon the earlier completion of all authorized transactions under the plan.
|
|
| Name | Michael Weintraub | |
| Title | chairperson of the Company’s Board of Directors | |
| Rule 10b5-1 Arrangement Adopted | true | |
| Adoption Date | June 6, 2024 | |
| Expiration Date | September 30, 2025 | |
| Arrangement Duration | 481 days | |
| Aggregate Available | 55,152 | 55,152 |
| Yvonne Hui [Member] | ||
| Trading Arrangements, by Individual | ||
| Material Terms of Trading Arrangement | On July 16, 2024, Yvonne Hui, the Principal Accounting Officer of the Company, adopted a Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Ms. Hui’s Rule 10b5-1 Trading Plan provides for the sale of up to 8,417 shares of common stock, plus an additional number of shares that Ms. Hui could receive upon the vesting of certain equity awards that may be granted pursuant to her first half fiscal 2025 bonus and certain equity awards that she may receive due to her participation in the Company’s Employee Stock Purchase Plan (“ESPP”), net of any shares sold in non-discretionary transactions pursuant to the Company’s mandatory sell-to-cover policy to cover Ms. Hui’s tax withholding obligations in connection with the vesting and settlement of restricted stock unit awards. The number of shares to be granted pursuant to Ms. Hui’s first half fiscal year 2025 bonus and to be purchased by Ms. Hui through the Company’s ESPP, and the number of shares to be sold by her to cover taxes, and thus the exact number of shares to be sold pursuant to Ms. Hui’s Rule 105b-1 Trading Plan, can only be determined upon the occurrence of future events. Ms. Hui’s Rule 10b5-1 Trading Plan expires on July 31, 2025, or upon the earlier completion of all authorized transactions under the plan.
|
|
| Name | Yvonne Hui, | |
| Title | Principal Accounting Officer | |
| Rule 10b5-1 Arrangement Adopted | true | |
| Adoption Date | July 16, 2024 | |
| Expiration Date | July 31, 2025 | |
| Arrangement Duration | 380 days | |
| Aggregate Available | 8,417 | 8,417 |
| David Linetsky, SVP [Member] | ||
| Trading Arrangements, by Individual | ||
| Material Terms of Trading Arrangement | On July 18, 2024, David Linetsky, SVP, Life Sciences of the Company, adopted a Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Linetsky’s Rule 10b5-1 Trading Plan provides for the potential exercise of vested stock options and the associated sale of up to 49,299 shares of the Company’s common stock, plus an additional number of shares that Mr. Linetsky could receive upon the vesting of certain equity awards that may be granted pursuant to his first half fiscal 2025 bonus, net of any shares sold in non-discretionary transactions pursuant to the Company’s mandatory sell-to-cover policy to cover Mr. Linetsky’s tax withholding obligations in connection with the vesting and settlement of restricted stock unit awards. The number of shares to be granted pursuant to Mr. Linetsky’s first half fiscal year 2025 bonus, and the number of shares to be sold by him to cover taxes, and thus the exact number of shares to be sold pursuant to Mr. Linetsky’s Rule 105b-1 Trading Plan, can only be determined upon the occurrence of future events. Mr. Linetsky’s Rule 10b5-1 Trading Plan expires on March 31, 2025, or upon the earlier completion of all authorized transactions under the plan.
|
|
| Name | David Linetsky | |
| Title | SVP, Life Sciences | |
| Rule 10b5-1 Arrangement Adopted | true | |
| Adoption Date | July 18, 2024 | |
| Expiration Date | March 31, 2025 | |
| Arrangement Duration | 256 days | |
| Aggregate Available | 49,299 | 49,299 |
| Evan Roberts December 2023 Plan [Member] | Evan Roberts [Member] | ||
| Trading Arrangements, by Individual | ||
| Material Terms of Trading Arrangement | On July 17, 2024, Evan Roberts, the Company’s Chief Operating Officer, terminated a Rule 10b5-1 Trading Plan he had previously adopted with respect to the sale of the Company’s common stock that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). It was adopted on December 21, 2023, established a plan with an end date of March 30, 2025, and provided for the sale of up to 84,712 shares of common stock pursuant to the terms of the plan. As of the date of termination of his Rule 10b5-1 Trading Plan, Mr. Roberts had sold 25,962 shares of common stock under its terms.
|
|
| Name | Evan Roberts | |
| Title | Chief Operating Officer | |
| Rule 10b5-1 Arrangement Terminated | true | |
| Termination Date | July 17, 2024 | |
| Aggregate Available | 84,712 | 84,712 |
| Evan Roberts July 2024 Plan [Member] | Evan Roberts [Member] | ||
| Trading Arrangements, by Individual | ||
| Material Terms of Trading Arrangement | In addition, on July 17, 2024, Mr. Roberts, adopted a new 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Roberts’ Rule 10b5-1 Trading Plan provides for the potential exercise of vested stock options and the associated sale of up to 58,750 shares of the Company’s common stock. The plan expires on July 18, 2025, or upon the earlier completion of all authorized transactions under the plan.
|
|
| Name | Mr. Roberts | |
| Rule 10b5-1 Arrangement Adopted | true | |
| Adoption Date | July 17, 2024 | |
| Expiration Date | July 18, 2025 | |
| Arrangement Duration | 366 days | |
| Aggregate Available | 58,750 | 58,750 |